Press Release (ePRNews.com) - TORONTO - Jun 19, 2018 - Join Kirsty Harper, Ph.D., MSc, BSc, head of biologics at Envigo, a leading provider of nonclinical contract research services and research models, on Wednesday, June 27, 2018, at 10 a.m. EDT (3 p.m. BST/UK), for an insightful and interactive presentation that will benefit vaccine developers, biopharmaceutical developers and immune profiling laboratories working in personalized medicine, translational medicine, immunotherapy and oncology.
The primary function of the immune system is to protect the body from infection by identifying and removing pathogens. A complex system, involving many individual cell populations, the immune system utilizes a range of mechanisms for the identification and subsequent removal of pathogens and other non-self material such as tumor cells.
Due to the efficiency of the immune system, a range of control mechanisms serve to ensure that the potentially damaging effects of these killing mechanisms are directed specifically at pathogens and resolved once the pathogen has been eliminated. Some of these control mechanisms utilize inhibitory pathways which mediate a negative signal to activated immune cells, instructing them to switch off.
This is an important method of restricting an immune response to the period of infection only, enabling it to revert to baseline when the pathogen has been eliminated, and defects in this system can lead to hypersensitivity or autoimmune disease. It is now known that tumors exploit this system to prevent immune attack by upregulating expression of these inhibitory or “checkpoint” markers to dampen the anti-tumor immune response.
Recently, this has become an area of interest for oncology. By blocking the negative signals mediated by checkpoint markers and effectively taking the brakes off the immune system, increased anti-tumor activity can be induced. However, the complex nature of the immune system also means that any changes to its overall function can potentially lead to negative consequences, and a thorough understanding of the biology mediated by each checkpoint inhibitor product is essential in order to fully assess the risk of any unwanted effects.
For more information about this complimentary event, visit Releasing the Immune System Brakes: The Importance of Modelling Effects in Non-Clinical Safety Studies.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Nima Rajan Source :
Tel: +1 (416) 977-6555 ext 352